Clinical trials in myasthenia gravis.

Myasthenia Gravis is a chronic autoimmune disease associated with autoantibodies that are directed against post synaptic acetyl choline receptors in 80-88%. Around 50% of patients will not respond to conventional treatment and disease course is often unpredictable with life-threatening myasthenic crises affecting 15-20% of patients at least once during their lives. MG-ADL scores improved from baseline to week 12, mean - 6 (95% CI - 9 to - 3), Quantitative Myasthenia Gravis score - 7 (- 11 to - 3), Myasthenia Gravis composite score - 14 (- 19 to - 9), and Myasthenia Gravis Quality of life 15-revised score - 9 (- 15 to - 3). [Extracted from the article]